Comparison of Traditional Dysphagia Therapy and Developed Protocol for Dysphagia Patients in Intensive Care Unit
Launched by RIPHAH INTERNATIONAL UNIVERSITY · May 27, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to treat dysphagia, which means difficulty swallowing, in patients who are in the intensive care unit (ICU). This condition can lead to serious problems like pneumonia and longer hospital stays. The study aims to compare a new treatment plan specifically designed for ICU patients with traditional methods to see which one works better for helping these patients swallow safely.
To participate in the trial, patients must be adults aged 18 or older who have been admitted to the ICU and diagnosed with dysphagia within 72 hours. They need to have a certain level of alertness, but those with pre-existing conditions affecting swallowing or who are expected to stay in the ICU for less than 48 hours will not be included. If eligible, participants can expect to receive either the new treatment approach or the standard therapy while being closely monitored. This study hopes to improve care for patients facing swallowing difficulties in critical situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (≥18 years) admitted to ICU with confirmed dysphagia by bedside evaluation within 72 hours of admission
- • GCS more then 8
- Exclusion Criteria:
- • Preexisting neurological disorders affecting swallowing, head and neck cancer, inability to follow commands, expected ICU stay \<48 hours
About Riphah International University
Riphah International University is a leading educational institution based in Pakistan, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to excellence in research and education, Riphah emphasizes ethical standards and scientific integrity in its clinical studies. The university collaborates with various stakeholders, including healthcare professionals and industry partners, to enhance patient outcomes and contribute to the global body of medical knowledge. Through its robust research programs, Riphah International University aims to foster a culture of inquiry and improve healthcare delivery both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lahore, Punjab, Pakistan
Patients applied
Trial Officials
Anum Ashraf, PhD*
Principal Investigator
Riphah International University
Nazia Mumtaz, PhD*
Study Director
Riphah International University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported